is inhibited by phosphorylation.
14 The majority of the human CDK phosphorylation sites in pRb have been reported to be involved in the regulation of RB-E2F interaction, including the sites Thr252, Thr356, Thr821, Thr826, Ser780, Ser788, Ser795, Ser807, Ser811 etc. 15 However, there has been no report about the role of functional inactivation of pRb by its hyperphosphorylation in pituitary tumorigenesis. The overexpressions of cyclin D1 and CDK4 have also never been studied in combination with pRb hyperphosphorylation in human PAs. The clinicopathologic correlation between these cell cycle regulators and the biologic behavior of PAs has not been examined much, although there is some data for their association with the hormonal functions of PA. Therefore, we investigated the immunohistochemical expressions of cyclin D1, CDK4 and phosphorylated pRb (p-pRb) in 50 PAs to establish the role of the functional inactivation of pRb associated with the cyclin D1/CDK4 overexpression in pituitary tumorigenesis, and we correlated this with the clinicopathologic variables.
MATERIALS AND METHODS

Patients and tissue samples
Fifty cases of pituitary adenoma were obtained from 47 patients who underwent tumor excision by a transsphenoidal approach (43 patients) or by craniotomy (4 patients) at Dankook University Hospital between 1996 and 2007. Forty-five primary and 5 recurrent tumors were included in this study, and two of the recurrent cases were operated on at this institute initially as recurrent PAs. Three recurrent PA samples were examined along with each corresponding primary tumor, and the intervals between the first and the second operation ranged from 2 to 5 years. Tumors were graded according to a modified Hardy classification. 16 Grade 1 tumors were microadenomas (<1 cm in diameter), and grade 2 tumors were enclosed macroadenomas (>1 cm in diameter) with or without suprasellar extension. Both the grade 1 and grade 2 tumors were considered to be noninvasive. Grade 3 tumors were locally invasive with evidence of bony destruction and tumor within the sphenoid and/or cavernous sinus. Grade 4 tumors demonstrated central nervous system/extracranial spreading with or without metastases. Both the grade 3 and 4 tumors were considered to be invasive. Clinical data such as age, gender, pituitary apoplexy, recurrence, and radiation therapy were also obtained from the medical records of the 47 patients.
Immuohistochemical analysis
The standard avidin-biotin-peroxidase complex method using the LSAB kit (DAKO, Glostrup, Denmark) was used for immunohistochemical staining with monoclonal antibodies against human cyclin D1 (SP4, NeoMarkers, Fremont, CA, USA), human CDK4 (C-22:sc-260, Santa Cruz Biotechnology, Santa Cruz, CA, USA), and human p-pRb (pT-356:EPR2153AY, Epitomics, Burlingame, CA, USA). The 4 μ m-thick tissue sections were deparaffinized with standard xylene and they were hydrated through a series of graded alcohol solutions. The sections were microwaved in 10 mM citrate buffer at 90℃ for 10 min and then treated with 3% H2O2-PBS solution to reduce the endogenous peroxidase activity. Then they were incubated with normal bovine serum to reduce the nonspecific antibody binding and they were subsequently subjected to the primary antibody reactions. The primary antibodies for the cyclin D1, CDK4 and p-pRb were reacted with the sections at room temperature for one hour at the dilution of 1:100, 1:400, and 1:100, respectively. Negative controls (pituitary tumors with the primary antibody omitted) were used for each series of staining. Human palatine tonsils for cyclin D1, normal human skin for CDK4 and human lung carcinoma for p-pRb were used as each positive control tissue, respectively. The sections were subjected to a color reaction with 3,3-diaminobenzidine tetrahydrochloride that contained 3% H2O2 in Tris buffer. They were lightly counterstained with Mayer's hematoxylin.
For evaluating the expressions of cyclin D1, CDK4 and p-pRb, the tumor cells were considered positive only when distinct nuclear staining was seen, regardless of the associated cytoplasmic staining, which was faint and considered non-specific. The cases were considered to be positive for cyclin D1 and CDK4 proteins, respectively, when more than 10% of tumor cells showed distinct nuclear positivity.
2 The positive cases for cyclin D1 and CDK4 were interpreted as cyclin D1 and CDK4 overexpression, respectively. Cases were regarded as being hyperphosphorylated (or positive) for p-pRb if either more than 5% of the tumor cell nuclei showed a distinct signal with moderate to strong intensity or more than 10% of the nuclei were stained recognizable but more obvious as compared to the internal normal controls. 16 Those cases with the positive immunostaining for p-pRb were considered to have functional pRb inactivation due to hyperphosphorylation at threonine 356. 15 
Statistical analysis
Comparison of the immunoreactivity between two-categori-cal clinicopathologic variables and the relationships between the altered expressions of cyclin D1, CDK4 and p-pRb were analyzed by chi-square tests (SPSS 15.0, Chicago, IL, USA). A pvalue less than 0.05 was defined as statistically significant.
RESULTS
Immunoexpression patterns of cyclin D1, CDK4 and p-pRb in 50 human pituitary adenomas These G1/S cell cycle regulator proteins showed distinct immunostaining specifically in the nuclei and not in the cytoplasm of the adenoma cells ( Fig. 1-3 ). Normal entrapped pituitary glands or stromal tissues showed neither cyclin D1 nor CDK4 immunopositivity. A p-pRb immunoexpression was never or only rarely found in the internal control tissues. The overexpression of cyclin D1 and CDK4 was demonstrated in 28 (56%) and 32 (64%) of the 50 PAs, respectively. Positive p-pRb staining was found in 32 (64%) of the cases, when the positive cases were interpreted to have the functionally inactivated pRb by its hyperphosphorylation. One or more of these instances of altered expression was observed in 41 cases (82%).
Inter-relationships between the altered expressions for cyclin D1, CDK4 and pRb (Table 1) Cyclin D1 overexpression was significantly correlated with p-pRb expression (p=0.038) (Table 1-A) . p-pRb expression was tightly correlated with CDK4 expression (p=0.020) (Table 1-B) . However, correlation between the cyclin D1 and CDK4 overexpressions was not evident, but this seemed to be marginally significant (p=0.083) (Table 1-C). These results showed the functional inactivation of pRb by its hyperphosphorylation was statistically clearly associated with the cyclin D1 and CDK4 overexpressions in human PAs.
Clinicopathologic data and its relationship with a solitary or combined overexpression of cyclin D1, CDK4 and p-pRb
The data is summarized in Table 2 . This study cohort consisted of 22 males and 25 females. The average age of the males was 47.6 years and that for the females was 43.8 years. The combined average age was 45.6 years. Of the 50 PAs, 26 were classified as clinically non-functioning based on the medical records and 24 as functioning adenomas (PRL, GH, ACTH, TSH and ADH). The functioning adenomas secreted the hormones of prolactin (PRL, 14), growth hormone (GH, 7), adrenocorticotropic hormone (ACTH, 5), thyroid stimulating hormone (TSH, 2) and antidiuretic hormone (ADH, 1). Among these, two cases showed mixed PRL and GH production, two mixed ACTH and TSH, and one mixed ACTH and ADH. According to a modified Hardy classification, 42 PAs (84%) were non-invasive with grade 1 or 2, and they usually showed micro-or macroadenomas (>1 cm) located within the sella turcica. Eight tumors (16%) were invasive with grade 3, and these tumors showed invasion to the cavernous or sphenoid sinus. There were no grade 4 tumors in this tumor cohort. Pituitary apoplexy, which is characterized by massive hemorrhagic infarct within the tumor, occurred in 7 cases (14%). All 7 tumors showing pituitary apoplexy displayed a cyclin D1 overexpression (100%), whereas 43 tumors with no pituitary apoplexy had 58% of cyclin D1 immunoreactivity (p=0.040). Most tumors with GH production (6/7, 86%) showed no or very low cyclin D1 immunoreactivity, and this was found to be inversely correlated with cyclin D1 overexpression (p=0.003). Each of the CDK4 and p-pRb expressions, as well as any combined expressions, never exhibited a significant association with the clinicopathologic variables.
DISCUSSION
The transition from G1 to S phase of the cell cycle is known to be regulated by mediators that result in pRb phosphorylation. Deregulation of this pathway has been extensively studied in numerous tumor types, as it might play a key role in tumorigenesis. [18] [19] [20] In human pituitary adenomas, the alterations in G1/S cell cycle regulation have not been extensively studied, so there are no data on CDK4 protein and phosphorylated pRb (p-pRb), although some data for cyclin D1 or E genes/protein and the genes for CDK4 and pRb has been accumulated to a degree.
2-9
According to the literature, 2-6 it has generally been reported that a cyclin D1 overexpression occurs at a relatively high frequency (49-54%) when detected by an immunohistochemical method and it is not correlated with the tumor grade or an allelic imbalance of the CCND1 gene.
2,4 Therefore, recent studies have described a possible role for cyclin D1 overexpression, which may be an early event in pituitary tumorigenesis. 4, 5 The data on CDK4 gene alterations has failed to reveal any consistent amplification or point mutations, and there are no reports on the CDK4 expression in human PAs.
2,3 Our findings such as the relatively high frequency of cyclin D1 and CDK4 overexpressions and the lack of a statistically significant difference in the frequency of these overexpressions between primary and recurrent adenomas suggest that these alterations occur early and they might be required events in human pituitary tumorigenesis. To best of our knowledge, this is the first report that a CDK4 overexpression might be a key component in pituitary tumorigenesis via the deregulation of G1/S cell cycle control. Deregulation of cyclin D1 synthesis has been reported to allow cell cycle progression in the absence of growth factors and may contribute to the initiation of oncogenesis.
21
Since RB gene inactivation is unlikely to play a role in pituitary tumorigenesis 8, 9 and shows no association with the loss of pRb, functional inactivation of pRb by its hyperphosphorylation could be the next topic of the study for pituitary tumorigenesis via the pRb pathway. In fact, it has been reported that hyperphosphorylation of pRb due to cyclin D1 or CDK4 may lead to uncontrolled cellular proliferation. [11] [12] [13] The biological significance of pRb hyperphosphorylation and its impact on the ordered progression through G1/S are exemplified by the amplification of the cyclin D1 gene in breast and esophageal cancer cells, which is believed to promote pRb phosphorylation. 22 The majority of the CDK phosphorylation sites in pRb are known to be involved in the regulation of RB-E2F interaction, including the sites Ser795, Ser811, Ser807, Thr821, Thr356 etc. 15 The primary anti-Rb phospho (pT356) antibody used in this study detected the increase in phosphorylated pRb (p-pRb) in the tumor cell nuclei in 32 (64%) of the 50 PAs. This immunostaining result suggests that hyperphosphorylated pRb plays an important role in human PAs via inactivating the growth suppression function of pRb.
Our data show that 75% and 79% of the tumors that overexpressed cyclin D1 and CDK4, respectively, also overexpressed p-pRb, with each correlation between the cyclin D1/CDK4 overexpression and the p-pRb expression (p=0.038 and 0.020) being statistically significant. These findings are consistent with the concensus that the overexpression of cyclin D1 leads to the increased phosphorylation of pRb, 18, 23 although no data on CDK4 overexpression has yet been accumulated. Thus, the functional inactivation of pRb following cell cycle-dependent hyperphosphorylation by the cyclin D1/CDK4 complex might play a key role in human pituitary tumorigenesis.
Aberrations of one or more components of the pRb/cyclin D1/ CDK4 pathway have been reported to occur as frequent events, with a reported frequency of 80-82% in sporadic human PAs.
2,3
In this study, 41 (82%) of the 50 PAs showed altered expressions of one or more proteins (cyclin D1, CDK4 and pRb), demonstrating a marked alteration in the RB1 pathway in human PAs.
